The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Faris F. Brkic, Stefan Stoiber, Marlene Friedl, Tobias Maier, Gregor Heiduschka, Lorenz Kadletz-Wanke
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	adenoid-cystic carcinoma fibrinogen-to-lymphocyte ratio prognostic marker survival outcome Medicine R
Acceso en línea:	https://doaj.org/article/9a85638b0b434d30837ed1ab36d8a0a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a85638b0b434d30837ed1ab36d8a0a3
record_format	dspace
spelling	oai:doaj.org-article:9a85638b0b434d30837ed1ab36d8a0a32021-11-25T18:08:10ZThe Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma10.3390/jpm111112282075-4426https://doaj.org/article/9a85638b0b434d30837ed1ab36d8a0a32021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1228https://doaj.org/toc/2075-4426Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (<i>n</i> = 28) compared to the high pretreatment FLR group (<i>n</i> = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; <i>p</i> = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; <i>p</i> = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.Faris F. BrkicStefan StoiberMarlene FriedlTobias MaierGregor HeiduschkaLorenz Kadletz-WankeMDPI AGarticleadenoid-cystic carcinomafibrinogen-to-lymphocyte ratioprognostic markersurvivaloutcomeMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1228, p 1228 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adenoid-cystic carcinoma fibrinogen-to-lymphocyte ratio prognostic marker survival outcome Medicine R
spellingShingle	adenoid-cystic carcinoma fibrinogen-to-lymphocyte ratio prognostic marker survival outcome Medicine R Faris F. Brkic Stefan Stoiber Marlene Friedl Tobias Maier Gregor Heiduschka Lorenz Kadletz-Wanke The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
description	Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (<i>n</i> = 28) compared to the high pretreatment FLR group (<i>n</i> = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; <i>p</i> = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; <i>p</i> = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.
format	article
author	Faris F. Brkic Stefan Stoiber Marlene Friedl Tobias Maier Gregor Heiduschka Lorenz Kadletz-Wanke
author_facet	Faris F. Brkic Stefan Stoiber Marlene Friedl Tobias Maier Gregor Heiduschka Lorenz Kadletz-Wanke
author_sort	Faris F. Brkic
title	The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_short	The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_full	The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_fullStr	The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_full_unstemmed	The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_sort	potential prognostic value of a novel hematologic marker fibrinogen-to-lymphocyte ratio in head and neck adenoid-cystic carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9a85638b0b434d30837ed1ab36d8a0a3
work_keys_str_mv	AT farisfbrkic thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT stefanstoiber thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT marlenefriedl thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT tobiasmaier thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT gregorheiduschka thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT lorenzkadletzwanke thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT farisfbrkic potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT stefanstoiber potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT marlenefriedl potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT tobiasmaier potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT gregorheiduschka potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma AT lorenzkadletzwanke potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
_version_	1718411574506422272

The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Ejemplares similares